Skip Navigation

Lotus Reported Unaudited January Revenues of NT$1,996 Million, surging 45.4% MoM

07 February 2024

Taipei, Taiwan, February 07, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for January 2024, reaching NT$1,996 million. This marks a remarkable 45.4% surge compared to the previous month, demonstrating a consistent performance on par with the same period last year.

In January, the Asian market had the similar revenue, but the export revenue surged. The export revenue for the month experienced an impressive growth of 131.1% compared to the previous month, mainly attributed to the replenishment of lenalidomide to the United States and Brazil. Notably, lenalidomide received approvals in Central American countries such as Guatemala, as well as in the Middle Eastern nations of the United Arab Emirates and Bahrain during this month.

Furthermore, Lotus Pharmaceutical's strategic partner, NRX Pharmaceuticals, has achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for this trial is anticipated in Q2 of this year.

Looking ahead, Lotus is poised to sustain steady growth in both the Asian and export markets throughout 2024. The company remains committed to expanding its portfolio in New Chemical Entities (NCE), 505(b)(2), and biosimilars, showcasing a dedication to ensuring sustainable growth across its overall operations.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Media Enquiries:

Susan Liao, IR/PR Director

+886 2 2700 5908